Saint Peter's University Hospital Balance Sheet June 30, 2019 (000's)

(000 0)	(Unaudited)
Assets	(Citation)
Current assets:	
Cash and cash equivalents	\$15,999
Patient accounts receivable, net	49,020
Assets whose use is limited, current portion	113,165
Supplies	5,619
Estimated third-party payer settlements, current portion	941
Due from related parties, current portion	5,887
Other current assets	10,592
Total current assets	201,223
	-, -
Assets whose use is limited, less current portion	15,657
Estimated third-party payer settlements less current portion	693
Beneficial interest in Foundation	6,054
Right to use leased assets	8,132
Property, plant, equipment and construction, net	179,206
Due from related parties, non current portion	2,127
Other assets	29,899
0.1.0. 0.0000	\$442,991
	<u> </u>
Liabilities and net assets	
Current liabilities:	
Current portion of long-term debt and line of credit	\$9,342
Current portion of lease liability	\$1,887
Accounts payable	22,564
Accrued expenses and other liabilities	32,465
Accrued interest	4,066
Estimated third-party payer settlements, current portion	2,188
Due to related parties	10,928
Total current liabilities	83,440
Long-term debt, less current portion	142,528
Long-term portion of lease liability	6,244
Accrued pension liability	123,411
Estimated third-party payer settlements, less current portion	2,077
Other liabilities	33,870
Total liabilities	391,570
Not accets:	
Net assets:	44 600
Net assets without donor restrictions	44,622
Net assets with donor restrictions Total net assets	6,799
ו טומו ווכו מססכוס	51,421 \$442,991
	Ψ++∠,υυ Ι

Saint Peter's University Hospital Statement of Operations and Changes in Net Assets June 30, 2019 (000's)

(000 3)	(Unaudited)
Revenue, gains and other support:	
Net patient service revenue	\$227,725
Other operating revenue, net	13,913
Net assets released from restriction	4
Total revenue, gains and other support	241,642
Expenses:	
Salaries and wages	111,130
Resident and physician fees	4,702
Employee benefits	26,614
Supplies and expenses	74,117
Governmental taxes, fees, and assessments	2,046
Interest	4,352
Depreciation and amortization	12,888
Total expenses	235,849
Income from operations	5,793
Equity in net earnings of joint ventures	154
Gain on sale of property, plant and equipment	61
Net change in unrealized gains and losses on equity investments	3,056
Non-operating net periodic pension cost	(1,916)
Excess of revenue over expenses	7,148
Net change in unrealized gains and losses on non-equity investments	1,889
Donated Equipment	1,427
Increase in net assets without donor restrictions	10,464
Net assets with donor restrictions	
Restricted gifts and contributions	4
Net change in beneficial interest in Foundation	121
Net assets released from restriction	(4)
Increase in net assets with donor restrictions	121
Increase in net assets	10,585
Net assets at beginning of year	40,836
Net assets as of June 30, 2019	\$51,421

Saint Peter's University Hospital Statement of Cash Flows Year ended June 30, 2019 (000's)

New String Activities String Activities	• •	(Unaudited)
Adjustments to reconcile increase in net assets to net cash provided by operating activities Depreciation and amortization Net change in unrealized gains and losses on investments (4,945) Net change in beneficial interest in Foundation (121) Donated equipment (1,427) Changes in operating assets and liabilities: Patient accounts receivable, net (33) Supplies and other assets (3,100) Due from related parties, net (1,058) Other assets (9,699) Accounts payable, accrued expenses, and other liabilities Estimated third-party payer settlements, net (1,218) Accrued pension liability Net cash provided by operating activities Investing Activities Cash received from joint ventures Alt (purchases) of assets whose use is limited (8,672) Purchases of property, plant, equipment and construction, net (5,799) Net cash used in investing activities Proceeds from the issuance of debt 2,878 Repayment of debt and capital leases Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents Cash & cash equivalents at December 31, 2018 Cash & cash equivalents at June 30, 2019 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Operating activities	
cash provided by operating activities Depreciation and amortization 12,888 Net change in unrealized gains and losses on investments (4,945) Net change in beneficial interest in Foundation (121) Donated equipment (1,427) Changes in operating assets and liabilities: Patient accounts receivable, net (33) Supplies and other assets (3,100) Due from related parties, net (1,058) Other assets (9,699) Accounts payable, accrued expenses, and other liabilities 11,226 Estimated third-party payer settlements, net (1,218) Accrued pension liability (841) Net cash provided by operating activities 12,250 Investing Activities Cash received from joint ventures 154 Net (purchases) of assets whose use is limited (8,672) Purchases of property, plant, equipment and construction, net (5,799) Net cash used in investing activities (14,317) Financing activities (3,978) Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167)	Increase in net assets	\$10,584
Net change in unrealized gains and losses on investments Net change in beneficial interest in Foundation (121) Donated equipment (1,427) Changes in operating assets and liabilities: Patient accounts receivable, net (33) Supplies and other assets (3,100) Due from related parties, net (1,058) Other assets (9,699) Accounts payable, accrued expenses, and other liabilities Estimated third-party payer settlements, net (1,218) Accrued pension liability (841) Net cash provided by operating activities Cash received from joint ventures 154 Net (purchases) of assets whose use is limited (8,672) Purchases of property, plant, equipment and construction, net (5,799) Net cash used in investing activities (14,317) Financing activities Proceeds from the issuance of debt Repayment of debt and capital leases Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents Cash & cash equivalents at December 31, 2018 Cash & cash equivalents at June 30, 2019 Supplemental disclosure of non-cash investing and financing activities and cash flow information	•	
Net change in beneficial interest in Foundation (121) Donated equipment (1,427) Changes in operating assets and liabilities: Patient accounts receivable, net (33) Supplies and other assets (3,100) Due from related parties, net (1,058) Other assets (9,699) Accounts payable, accrued expenses, and other liabilities 11,220 Estimated third-party payer settlements, net (1,218) Accrued pension liability (841) Net cash provided by operating activities 12,250 Investing Activities Cash received from joint ventures 154 Net (purchases) of assets whose use is limited (8,672) Purchases of property, plant, equipment and construction, net (5,799) Net cash used in investing activities (14,317) Financing activities Proceeds from the issuance of debt 2,878 Repayment of debt and capital leases (3,978) Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167) Cash & cash equivalents at December 31, 2018 19,166 Cash & cash equivalents at June 30, 2019 \$15,999 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Depreciation and amortization	12,888
Changes in operating assets and liabilities: Patient accounts receivable, net (33) Supplies and other assets (3,100) Due from related parties, net (1,058) Other assets (9,699) Accounts payable, accrued expenses, and other liabilities 11,220 Estimated third-party payer settlements, net (1,218) Accrued pension liability (841) Net cash provided by operating activities 12,250 Investing Activities 154 Cash received from joint ventures 154 Net (purchases) of assets whose use is limited (8,672) Purchases of property, plant, equipment and construction, net (5,799) Net cash used in investing activities (14,317) Financing activities 2,878 Repayment of debt and capital leases (3,978) Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167) Cash & cash equivalents at December 31, 2018 19,166 Cash & cash equivalents at June 30, 2019 \$15,999 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Net change in unrealized gains and losses on investments	(4,945)
Changes in operating assets and liabilities: Patient accounts receivable, net (33) Supplies and other assets (3,100) Due from related parties, net (1,058) Other assets (9,699) Accounts payable, accrued expenses, and other liabilities 11,220 Estimated third-party payer settlements, net (1,218) Accrued pension liability (841) Net cash provided by operating activities 12,250 Investing Activities Cash received from joint ventures 154 Net (purchases) of assets whose use is limited (8,672) Purchases of property, plant, equipment and construction, net (5,799) Net cash used in investing activities (14,317) Financing activities Proceeds from the issuance of debt 2,878 Repayment of debt and capital leases (3,978) Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167) Cash & cash equivalents at December 31, 2018 19,166 Cash & cash equivalents at June 30, 2019 \$15,999 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Net change in beneficial interest in Foundation	(121)
Patient accounts receivable, net (33) Supplies and other assets (3,100) Due from related parties, net (1,058) Other assets (9,699) Accounts payable, accrued expenses, and other liabilities 11,220 Estimated third-party payer settlements, net (1,218) Accrued pension liability (841) Net cash provided by operating activities 12,250 Investing Activities Cash received from joint ventures 154 Net (purchases) of assets whose use is limited (8,672) Purchases of property, plant, equipment and construction, net (5,799) Net cash used in investing activities (14,317) Financing activities Proceeds from the issuance of debt 2,878 Repayment of debt and capital leases (3,978) Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167) Cash & cash equivalents at December 31, 2018 19,166 Cash & cash equivalents at June 30, 2019 \$115,999 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Donated equipment	(1,427)
Supplies and other assets (3,100) Due from related parties, net (1,058) Other assets (9,699) Accounts payable, accrued expenses, and other liabilities 11,220 Estimated third-party payer settlements, net (1,218) Accrued pension liability (841) Net cash provided by operating activities 12,250 Investing Activities Cash received from joint ventures 154 Net (purchases) of assets whose use is limited (8,672) Purchases of property, plant, equipment and construction, net (5,799) Net cash used in investing activities (14,317) Financing activities Proceeds from the issuance of debt 2,878 Repayment of debt and capital leases (3,978) Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167) Cash & cash equivalents at December 31, 2018 19,166 Cash & cash equivalents at June 30, 2019 \$15,999 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Changes in operating assets and liabilities:	
Due from related parties, net Other assets Other assets Other assets Accounts payable, accrued expenses, and other liabilities Estimated third-party payer settlements, net Accrued pension liability Net cash provided by operating activities Investing Activities Cash received from joint ventures Act (purchases) of assets whose use is limited Net (purchases) of assets whose use is limited Net cash used in investing activities Financing activities Proceeds from the issuance of debt Repayment of debt and capital leases Net cash used by financing activities Net decrease in cash & cash equivalents Cash & cash equivalents at December 31, 2018 Cash & cash equivalents at June 30, 2019 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Patient accounts receivable, net	(33)
Other assets (9,699) Accounts payable, accrued expenses, and other liabilities 11,220 Estimated third-party payer settlements, net (1,218) Accrued pension liability (841) Net cash provided by operating activities 12,250 Investing Activities Cash received from joint ventures 154 Net (purchases) of assets whose use is limited (8,672) Purchases of property, plant, equipment and construction, net (5,799) Net cash used in investing activities (14,317) Financing activities Proceeds from the issuance of debt 2,878 Repayment of debt and capital leases (3,978) Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167) Cash & cash equivalents at December 31, 2018 19,166 Cash & cash equivalents at June 30, 2019 \$15,999 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Supplies and other assets	(3,100)
Accounts payable, accrued expenses, and other liabilities Estimated third-party payer settlements, net (1,218) Accrued pension liability Net cash provided by operating activities Investing Activities Cash received from joint ventures 154 Net (purchases) of assets whose use is limited Net (purchases) of assets whose use is limited Purchases of property, plant, equipment and construction, net (5,799) Net cash used in investing activities Financing activities Proceeds from the issuance of debt Repayment of debt and capital leases Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167) Cash & cash equivalents at December 31, 2018 Cash & cash equivalents at June 30, 2019 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Due from related parties, net	(1,058)
Estimated third-party payer settlements, net Accrued pension liability Net cash provided by operating activities Investing Activities Cash received from joint ventures 154 Net (purchases) of assets whose use is limited (8,672) Purchases of property, plant, equipment and construction, net (5,799) Net cash used in investing activities (14,317) Financing activities Proceeds from the issuance of debt Repayment of debt and capital leases (3,978) Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167) Cash & cash equivalents at December 31, 2018 Cash & cash equivalents at June 30, 2019 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Other assets	(9,699)
Accrued pension liability Net cash provided by operating activities Investing Activities Cash received from joint ventures Cash received from joint ventures 154 Net (purchases) of assets whose use is limited (8,672) Purchases of property, plant, equipment and construction, net (5,799) Net cash used in investing activities (14,317) Financing activities Proceeds from the issuance of debt 2,878 Repayment of debt and capital leases (3,978) Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167) Cash & cash equivalents at December 31, 2018 Cash & cash equivalents at June 30, 2019 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Accounts payable, accrued expenses, and other liabilities	11,220
Net cash provided by operating activities Investing Activities 2 (a) 154 Cash received from joint ventures 154 Net (purchases) of assets whose use is limited (8,672) Purchases of property, plant, equipment and construction, net (5,799) Net cash used in investing activities (14,317) Financing activities Proceeds from the issuance of debt 2,878 Repayment of debt and capital leases (3,978) Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167) Cash & cash equivalents at December 31, 2018 19,166 Cash & cash equivalents at June 30, 2019 \$15,999 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Estimated third-party payer settlements, net	(1,218)
Investing Activities Cash received from joint ventures 154 Net (purchases) of assets whose use is limited (8,672) Purchases of property, plant, equipment and construction, net (5,799) Net cash used in investing activities (14,317) Financing activities Proceeds from the issuance of debt 2,878 Repayment of debt and capital leases (3,978) Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167) Cash & cash equivalents at December 31, 2018 19,166 Cash & cash equivalents at June 30, 2019 \$15,999 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Accrued pension liability	(841)
Cash received from joint ventures 154 Net (purchases) of assets whose use is limited (8,672) Purchases of property, plant, equipment and construction, net (5,799) Net cash used in investing activities (14,317) Financing activities Proceeds from the issuance of debt 2,878 Repayment of debt and capital leases (3,978) Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167) Cash & cash equivalents at December 31, 2018 19,166 Cash & cash equivalents at June 30, 2019 \$15,999 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Net cash provided by operating activities	12,250
Net (purchases) of assets whose use is limited (8,672) Purchases of property, plant, equipment and construction, net (5,799) Net cash used in investing activities (14,317) Financing activities Proceeds from the issuance of debt 2,878 Repayment of debt and capital leases (3,978) Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167) Cash & cash equivalents at December 31, 2018 19,166 Cash & cash equivalents at June 30, 2019 \$15,999 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Investing Activities	
Purchases of property, plant, equipment and construction, net Net cash used in investing activities Financing activities Proceeds from the issuance of debt Repayment of debt and capital leases Net cash used by financing activities Net decrease in cash & cash equivalents Cash & cash equivalents at December 31, 2018 Cash & cash equivalents at June 30, 2019 Supplemental disclosure of non-cash investing and financing activities and cash flow information (14,317) (14,317) (2,878) (3,978) (1,100) (3,167) (3,167)	Cash received from joint ventures	154
Net cash used in investing activities Financing activities Proceeds from the issuance of debt Repayment of debt and capital leases (3,978) Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167) Cash & cash equivalents at December 31, 2018 Cash & cash equivalents at June 30, 2019 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Net (purchases) of assets whose use is limited	(8,672)
Financing activities Proceeds from the issuance of debt 2,878 Repayment of debt and capital leases (3,978) Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167) Cash & cash equivalents at December 31, 2018 19,166 Cash & cash equivalents at June 30, 2019 \$15,999 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Purchases of property, plant, equipment and construction, net	(5,799)
Proceeds from the issuance of debt Repayment of debt and capital leases Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167) Cash & cash equivalents at December 31, 2018 Cash & cash equivalents at June 30, 2019 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Net cash used in investing activities	(14,317)
Proceeds from the issuance of debt Repayment of debt and capital leases Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167) Cash & cash equivalents at December 31, 2018 Cash & cash equivalents at June 30, 2019 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Financing activities	
Repayment of debt and capital leases Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167) Cash & cash equivalents at December 31, 2018 Cash & cash equivalents at June 30, 2019 Supplemental disclosure of non-cash investing and financing activities and cash flow information		2,878
Net cash used by financing activities (1,100) Net decrease in cash & cash equivalents (3,167) Cash & cash equivalents at December 31, 2018 19,166 Cash & cash equivalents at June 30, 2019 \$15,999 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Repayment of debt and capital leases	(3,978)
Cash & cash equivalents at December 31, 2018 Cash & cash equivalents at June 30, 2019 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Net cash used by financing activities	
Cash & cash equivalents at June 30, 2019 \$15,999 Supplemental disclosure of non-cash investing and financing activities and cash flow information	Net decrease in cash & cash equivalents	(3,167)
Supplemental disclosure of non-cash investing and financing activities and cash flow information	Cash & cash equivalents at December 31, 2018	19,166
financing activities and cash flow information	Cash & cash equivalents at June 30, 2019	\$15,999
-	• • • • • • • • • • • • • • • • • • • •	
	_	\$4,066